WHIN — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases.
BiotechDigital HealthHealthtechNew Haven, US
Paul Fonteyne(Co-Founder)Stephen Strittmatter(Scientific Founder)Stephen Bloch(CEO, Co-Founder)Timothy Siegert(COO, Co-Founder)Jennifer Gabler(Executive Officer)
BoardRobert A. Bettigole(Director)in
Board seatGregory P HoGregory P. Ho· per SEC Form D · $30M raise · filed May 2026
Co-investorsElm Street VenturesSpring Mountain CapitalConnecticut Innovations
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.